Taejoon Pharmaceutical Co., Ltd.
Clinical trials sponsored by Taejoon Pharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- A multi-center, randomized, Double-Blind, Placebo-Controlled, parallel design, phase ⅱ clinical trial to evaluate the safety and efficacy of TJO-087 Results expected Oct 2026 (estimated)
- A daily eye drop might slow childhood nearsightedness. a trial puts it to the test. Results expected Apr 2027 (estimated)
-
A daily eye drop might slow childhood nearsightedness. a trial puts it to the test.
Disease control OngoingThis phase 3 trial tests whether an experimental eye drop called CTO0308 can slow the progression of myopia, or nearsightedness, in children aged 5 to 12. Participants receive either the active drop or a placebo once daily in each eye for 12 months. Researchers measure changes in…
Phase 3 • Sponsor: Taejoon Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
A multi-center, randomized, Double-Blind, Placebo-Controlled, parallel design, phase ⅱ clinical trial to evaluate the safety and efficacy of TJO-087
OngoingThis study aims to evaluate the therapeutic efficacy and safety of investigational product compared with placebo in adult patients with dry eye disease. Patients will receive investigational product or placebo for 3 months, and the therapeutic effect will be assessed based on the…
Phase 2 • Sponsor: Taejoon Pharmaceutical Co., Ltd.
Last updated Sep 10, 2026 02:00 UTC